Image courtesy of Bayer

Bayer invests USD 50 Million in eGenesis Series B financing round

Originally posted on Bayer.com

Investment to support development of human-compatible xeno organs to address the global organ shortage crisis / eGenesis with lead program in kidney transplantation

Bayer Photo
Research in the eGenesis laboratory, Cambridge, MA, USA

Leverkusen, Germany and Boston, Mass., November 7, 2019 – eGenesis, a biotechnology company utilizing breakthrough gene editing technologies for the development of effective human-compatible organs to address the global organ shortage, successfully completed a USD 100 million Series B financing. The financing was led by Fresenius Medical Care Ventures (FMCV), with participation from new investors including Leaps by Bayer and Wellington Partners. Existing investors, including, but not limited to, ARCH Venture Partners, Biomatics Capital, Alta Partners, and Khosla Ventures, all participated.

eGenesis is committed to helping solve the global organ shortage by pioneering an alternative source of human-compatible organs. It is currently estimated that there are between 1.5 to 2 million people on the organ transplant waitlist globally. This financing will enable the acceleration of the eGenesis kidney xenotransplant program into the clinic, as well as support advancement of a range of other xenotransplant programs across islet cell, liver, heart, and lung. The focus of the company is to rapidly advance an entirely new set of options across the transplantation field.

“Leaps by Bayer” is built for the specific purpose of tackling fundamental breakthrough solutions in the fields of health and nutrition with the help of new technologies. Sustainable organ replacement is one of the ten areas of engagement and investment (called “leaps”) for Leaps by Bayer. “We believe eGenesis is poised to revolutionize the entire organ transplantation market. This could save lives in a way that was previously not thought possible just a few years ago,” noted Jürgen Eckhardt, Head of Leaps by Bayer. Eckhardt and Dr. Lucio Iannone will represent Leaps by Bayer by actively participating on the eGenesis Board of Directors.

“eGenesis has a bold vision to solve the organ shortage crisis through xenotransplantation,” said Paul Sekhri, president and chief executive officer of eGenesis. “As we look ahead, we are proud to partner with Leaps by Bayer who has demonstrated a commitment for ushering in paradigm-shifting advances in the life sciences that will bring forward tomorrow’s medicines.”

Kemal Malik, Member of the Board of Management, Bayer AG, and responsible for Innovation, added, “Within Bayer’s innovation strategy, Leaps is driving breakthrough invention at Bayer and the eGenesis approach represents a truly transformational option, addressing the unmet medical need of patients suffering from a disease where organ transplantation could be a potentially lifesaving treatment.”

Leaps by Bayer, a unit of Bayer is investing into solutions to some of today’s biggest challenges in health and agriculture. Previous Leaps investments into potentially breakthrough technologies include Casebia Therapeutics (Cure genetic diseases), BlueRock Therapeutics (Regenerate lost tissue function), Joyn Bio (Reduce environmental impact of farming) as well as Khloris, Century Therapeutics and Pyxis Oncology (Prevent and cure cancer).

Latest News

Mastercard Names Ellen Jackowski Chief Sustainability Officer

Originally published at mastercard.com. Mastercard ranked No. 2 on The DiversityInc Top 50 Companies for Diversity list in 2022.   Mastercard announced Ellen Jackowski will join the company as Chief Sustainability Officer starting July 25, 2022. In this role, she will be instrumental in further integrating Mastercard’s Environmental, Social and Governance…

Seven Startups Join Mastercard Start Path Program, Supporting Underrepresented Founders

Originally published at mastercard.com. Mastercard ranked No. 2 on The DiversityInc Top 50 Companies for Diversity list in 2022.   Mastercard is expanding its award-winning Start Path startup engagement program to include seven early and late-stage startups hailing from the United States, Canada and Latin America. Carbon Neutral Club, Guava, oneKIN, Palla, SUMA…